Connor, Clark & Lunn Investment Management (CC&L)
HARP

Connor, Clark & Lunn Investment Management (CC&L)’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,487
Closed -$74K – 1241
2022
Q1 		$74K Sell
1,487
-873
-37% -$45.2K ﹤0.01% 991
2021
Q4 		$178K Buy
2,360
+1,237
+110% +$84.4K ﹤0.01% 993
2021
Q3 		$89K Buy
+1,123
New +$113K ﹤0.01% 989

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s HARP Position: Q2 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 1,487 shares — an estimated $74K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in HARP in Q3 2021 and held it in 3 quarters. The position peaked at $178K in Q4 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,487 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $74K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Harpoon Therapeutics, Inc. Common Stock position peaked at $178K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2022, filed 5 Aug 2022.